A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had:
* an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or
* TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together.
Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting).
The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding.
The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it.
Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health.
Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months.
Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned.
During the study, the study team will:
* Check vital signs such as blood pressure and heart rate
* Examine the participants' heart health using an electrocardiogram (ECG)
* Take blood samples
* Ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.

Start Date26 Jan 2023

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Asundexian

100 Translational Medicine associated with Asundexian

100 Patents (Medical) associated with Asundexian

Literatures (Medical) associated with Asundexian

01 Apr 2026·BIOORGANIC CHEMISTRY

Development of selective NBD-based fluorescent probes for in vitro detection of factor XIa and Thrombus imaging

Article

Author: Yang, Han ; Zou, Meijuan ; Li, Qing ; Zhou, Fengjiao ; Zhuang, Xinyu ; Zhao, Xingyu ; Li, Ruixing

Factor XIa (FXIa) is a promising target for safer anticoagulants. Herein, a series of NBD-based fluorescent probes (FNC2-FNC6) were developed by linking an FXIa inhibitor scaffold to an NBD fluorophore via alkyl chains of varying lengths. Molecular dynamics simulations revealed that shorter linkers, especially a two‑carbon chain, stabilize NBD binding in the FXIa pocket, enhancing fluorescence. Among these probes, FNC2 displayed potent FXIa inhibition (Ki = 14.2 nM) and selectivity over related proteases. It exhibited linear fluorescence increase upon FXIa binding (R² = 0.9952; LOD = 1.19 μg/mL), enabling accurate quantification in immunoglobulin products (recovery: 94.41%-103.76%; RSD < 2%). FNC2 visualized FXIa in human plasma clots with 2.7-fold higher signal than free NBD, suppressed dose-dependently by asundexian. This structure-guided approach yields selective probes for FXIa detection and thrombus imaging.

01 Feb 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of novel FXIa inhibitors featuring five-membered heterocycles as P2’ fragments

Article

Author: Gong, Ping ; Zhu, Huachao ; Wang, Tonghui ; Wu, Jie ; Wang, Xiaoqian

Thrombus formation within blood vessels poses a serious threat to human health and is closely associated with various cardiovascular disorders. Therefore, developing novel anticoagulants with reduced bleeding risk holds significant clinical importance. Factor XIa (FXIa), a key enzyme in the intrinsic coagulation pathway, has emerged as an attractive target for safer anticoagulant therapy. In this study, a series of novel small-molecule FXIa inhibitors were designed based on the scaffold of Asundexian through a bioisosteric replacement strategy. Starting from compound F22, structural optimization at the P2' region was conducted by replacing the amide with non-classical heterocycles, aiming to improve inhibitory potency, selectivity, and metabolic stability. Among the synthesized analogs, compound FE12 exhibited potent FXIa inhibition (IC₅₀ = 4.4 nM), high selectivity over PKal (SI = 60.3), and favorable metabolic stability (T_1/2 = 38.6 min in HLMs). Consistent with the in vitro enzyme assay, FE12 significantly prolonged aPTT in a dose-dependent manner, comparable to Asundexian. Molecular docking indicated that FE12 retains key hydrogen-bonding and water-mediated interactions within the FXIa active site, whereas its conformation in PKal shifts and loses these interactions, explaining its potent FXIa inhibitory activity and weak PKal inhibition. In the FeCl₃-induced rat thrombosis model, FE12 effectively inhibited thrombus formation comparable to Asundexian. In the mouse tail bleeding assay, FE12 did not cause a significant prolongation of bleeding time, indicating a minimal effect on hemostasis. Furthermore, acute toxicity evaluation demonstrated its good safety and tolerability. Overall, FE12 exhibits an excellent balance of potency, selectivity and safety, representing a promising lead compound for the development of small-molecule FXIa inhibitors.

01 Jan 2026·CPT-Pharmacometrics & Systems Pharmacology

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events

Article

Author: Garmann, Dirk ; Yassen, Ashraf ; Mundl, Hardi ; Kanefendt, Friederike ; Zisowsky, Jochen ; Vis, Peter ; Berkhout, Jan ; Broeker, Astrid

ABSTRACT:

Asundexian is a potent, selective, and reversible inhibitor of activated clotting Factor XI currently under development for secondary prevention of recurrent ischemic stroke in the ongoing Phase III OCEANIC‐STROKE study (NCT05686070). Here, we report the development of a population pharmacokinetic (popPK) model for asundexian. Plasma concentration data were available from 2914 participants enrolled in nine Phase I and II studies of asundexian. The pharmacokinetics (PK) of asundexian were well described by the popPK model. Within the investigated dose range of asundexian 10–100 mg once daily, the PK of asundexian was dose‐proportional. The systemic apparent clearance (CL/F) of asundexian was estimated to be 2.25 L/h and the central volume of distribution ( VC /F) was 35.3 L. Body weight, age, sex, concomitant administration of cytochrome P450 3A4 (CYP3A4) inhibitors, and renal function were identified as statistically significant covariates influencing the PK of asundexian. After accounting for differences in the distribution of these covariates, the PK of asundexian was comparable in healthy participants and participants at risk for thromboembolic/cardiovascular events. Similarly, no significant differences in PK were noted among participants with atrial fibrillation, ischemic stroke, or acute myocardial infarction. No clinically relevant covariates were identified that would warrant dose adjustments in various special populations of interest, including those defined by body weight, age, sex, and renal function, for the prevention of secondary ischemic strokes.

News (Medical) associated with Asundexian

05 Feb 2026

·www.businesswire.com

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared to placebo, both in combination with antiplatelet therapy These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke, or the severity of the stroke There was no increase in ISTH major bleeding, and the bleeding risk was similar to placebo for minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage, and fatal bleeding OCEANIC-STROKE enrolled 12,327 patients and is the first successfully completed Phase III trial of a FXIa inhibitor which demonstrated superiority in preventing stroke compared to placebo NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in the risk of ISTH (International Society of Thrombosis and Hemostasis) major bleeding. These findings were consistent regardless of age or sex, index event (stroke or high-risk TIA), stroke subtype, NIHSS (National Institutes of Health Stroke Scale), and acute stroke therapy like thrombolysis or planned secondary prevention strategies SAPT or DAPT. The results were presented at the International Stroke Conference 2026 in New Orleans. OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor which demonstrated superiority in reducing recurrent ischemic stroke compared to placebo. “A stroke is a life-changing event for patients and a major public health burden. The findings from OCEANIC-STROKE are a notable research achievement, demonstrating a substantial reduction in the risk of stroke with asundexian compared to placebo, alongside a sustained treatment effect and a safety profile with no observed increase in ISTH major bleeding,” said Mike Sharma, M.D., Principal Investigator of the OCEANIC-STROKE study, Michael G. DeGroote Chair in Stroke Prevention, McMaster University and Senior Scientist at Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences. “For clinicians and researchers who have spent decades working to reduce the global burden of secondary stroke, the OCEANIC-STROKE results represent the kind of scientific progress the field has long been striving to achieve.” Alongside the primary findings, secondary endpoints showed asundexian reduced the risk of a stroke of any kind (ischemic and hemorrhagic) by 26% (6.6% vs. 8.8%; csHR 0.74; 95% CI, 0.65 to 0.84; p<.0001) compared to placebo. In addition, the following secondary efficacy endpoints were met for asundexian compared to placebo, both in combination with antiplatelet therapy: the composite endpoint of cardiovascular death, myocardial infarction (MI) or stroke, and the composite of death from any cause, MI or stroke. For the safety analyses, there was no increase in the rate of ISTH major bleeding between asundexian compared to placebo (1.9% vs. 1.7%; HR 1.10; 95% CI, 0.85–1.44). For the pre-specified secondary safety endpoints, the risk of bleeding was similar compared to the rates seen in the placebo arm. OCEANIC-STROKE enrolled all common stroke subtypes in its design, classified by the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria. Among patients with an index ischemic stroke, the study enrolled patients with large-artery atherosclerosis (43%), small-vessel occlusion (lacune) (23%), stroke of undetermined etiology (30%), other determined etiology (3%), and cardioembolic stroke (2%). Across all TOAST subtypes evaluated, rates of recurrent ischemic stroke were lower with asundexian compared with placebo. “The consistent reduction in secondary events with asundexian across all types of strokes included in the trial, is particularly striking,” said Ashkan Shoamanesh, M.D., Co-Principal Investigator of OCEANIC-STROKE study and PHRI senior scientist. “OCEANIC-STROKE was deliberately designed with the goal of making the findings generalizable to the many ways stroke presents in clinical practice. These results provide confidence that, if approved, asundexian could become an important option for secondary stroke prevention across a broad range of stroke patients.” Each year, approximately 12 million people worldwide will experience a stroke, including nearly 800,000 people in the United States alone. Of these, 20-30% will be a recurrent stroke. Despite available secondary stroke prevention options, the risk of secondary stroke remains high. One in five stroke survivors will have another stroke within five years. Stroke is the second leading cause of death globally, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk than the first stroke. “OCEANIC-STROKE marks an important milestone that reflects the scientific ambition of Bayer and the global study teams who came together to challenge the boundaries of stroke prevention research,” said Yesmean Wahdan, M.D., Senior Vice President, U.S. Medical Affairs, Bayer. “To share these results with the global stroke community is deeply rewarding and underscores Bayer’s continued commitment to advancing aspirational research in areas of thrombotic disease. Most importantly, we know these efforts may matter most for the many stroke survivors for whom reducing the risk of another stroke remains an urgent need.” Asundexian has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for stroke prevention in patients after a non-cardioembolic ischemic stroke. Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. About OCEANIC-STROKE The OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary endpoint was time to ischemic stroke; the primary safety endpoint was major bleeding. About FXIa inhibitors Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. We have set a clear focus on developing innovative therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com. Find more information at: Health for all, Hunger for none | Bayer United States Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Clinical ResultPhase 3Fast Track

05 Feb 2026

·www.fiercebiotech.com

Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA

Guggenheim Securities analysts valued the stroke opportunity at $3 billion to $4 billion. \n Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication. The German drugmaker reported the study met its primary endpoint in November, providing a boost for the program and factor XIa inhibition more broadly after setbacks to asundexian and BMS and J&J’s rival drug candidate milvexian. Yet the lack of data in Bayer’s top-line release left unanswered questions about the clinical significance of the statistical success. Bayer answered the questions Thursday, using the International Stroke Conference 2026 in New Orleans to present data from the trial. The headline finding is that asundexian cut ischemic stroke by 26% after a noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), also called a mini-stroke.On an earnings call in May, Stefan Oelrich, head of Bayer’s pharma division, said the company focused the phase 3 trial on the subgroup in which it saw the biggest effect in phase 2. The company reported a 36% reduction in the risk of recurrent symptomatic ischemic stroke and TIA in the phase 2 subgroup. For comparison, BMS and J&J saw a 30% relative risk reduction in symptomatic ischemic strokes in their phase 2 trial. Asundexian reduced the stroke rate in the phase 3 trial without increasing major bleeding, which affected 1.9% of people on the study drug and 1.7% of their counterparts on placebo. Bayer said the risks of minor bleeding, hemorrhagic stroke, symptomatic intracranial hemorrhage and fatal bleeding were similar on asundexian and placebo.The potential to clear clots without raising bleeding risk is central to the promise of factor XIa inhibitors. While other anticoagulants affect hemostasis and thrombosis, factor XIa inhibition could decouple the mechanisms to deliver at least comparable efficacy and better safety than existing treatments.Bayer reported the phase 3 trial met multiple secondary endpoints, including by linking asundexian to a 26% reduction in the risk of a stroke of any kind compared to placebo. The secondary analysis included hemorrhagic strokes. Bayer also hit a composite endpoint of cardiovascular death, myocardial infarction (MI) or stroke as well as the composite of death from any cause, MI or stroke.Ashkan Shoamanesh, M.D., the trial’s co-principal investigator, said in a statement that the consistent reduction in secondary events with asundexian across all types of strokes is particularly striking. The results provide confidence that asundexian, if approved, could be an important option for secondary stroke prevention across a broad range of patients, Shoamanesh said. At the J.P. Morgan Healthcare Conference in January, Bayer\'s Oelrich said the pharma was engaging with health authorities and aiming to win approval this year. The timeline would put Bayer “well ahead of any competitor in this space, which will allow us to clearly set the scene and once again prove what I call our secret sauce in cardiovascular because we believe that we\'re a true leader in this space,” Oelrich said.BMS and J&J expect to publish phase 3 results for milvexian in secondary stroke prevention in the second half of 2026. The companies are gearing up to compete for a stroke market that Guggenheim Securities analysts valued at $3 billion to $4 billion in a note to investors in November. The analysts estimated atrial fibrillation, where Bayer has already failed, is a $15 billion opportunity.

Clinical ResultPhase 3Phase 2

05 Feb 2026

·endpoints.news

Bayer’s next-gen blood thinner reduced ischemic strokes by 26% in Phase 3 win

Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by 26% versus placebo when added to standard-of-care antiplatelet treatment, according to trial results presented Thursday at the International Stroke Conference in New Orleans. In a surprise for the drug class, Bayer said in November that asundexian met the study’s primary endpoint , but didn’t share numbers at the time. The OCEANIC-STROKE trial enrolled more than 12,000 people who had a non-cardioembolic ischemic stroke or high-risk transient ischemic attack in the 72 hours prior to treatment. “What is important when we look at these results is that this patient population has not seen any advancement in treatment over — depending on how you look at it — the last 15 to 20 years,” Christoph Koenen, Bayer’s head of clinical development and operations, told Endpoints News . Bayer plans to file the data with regulators, but Koenen declined to share timelines. The company previously projected asundexian could hit over €5 billion ($5.9 billion) in peak sales. Around 12 million people have a stroke every year, and about 20% to 30% of those cases are recurrent strokes, according to the company. Ischemic strokes occur when a blood clot cuts off blood supply to the brain, while a high-risk transient ischemic attack, also known as a “mini-stroke,” involves a temporary blockage of blood flow to the brain. A non-cardioembolic ischemic stroke is one that’s not caused by a blood clot in the heart. Asundexian inhibits a protein called factor XIa which plays a key role in excessive blood-clotting, Koenen said. He added the mechanism shouldn’t increase the risk of bleeding events because factor XIa doesn’t interfere as much with the normal repair mechanisms that stop bleeding. The results of OCEANIC-STROKE show this hypothesis is true, Koenen said. Around 1.9% of treated patients in the trial experienced a major bleeding event, compared with 1.7% of placebo patients. Fatal bleeding occurred in less than 1% of patients in both arms. Bayer hasn’t always had a smooth ride with asundexian. In 2022, the drug failed a Phase 2b trial that enrolled similar patients to OCEANIC-STROKE but had a different composite endpoint. The following year, the company terminated a Phase 3 study of asundexian in patients with atrial fibrillation at risk of stroke because it did worse than the active control arm. The success of OCEANIC-STROKE has revived interest in other drugs with the same mechanism, including Bristol Myers Squibb and Johnson & Johnson’s milvexian. Milvexian is currently being tested in a Phase 3 trial called Librexia STROKE, which is enrolling the same kind of patients as Bayer’s study. Earlier this month, Leerink analysts said they expect an 80% chance of success for the milvexian trial given Bayer’s results.

Phase 3Clinical ResultPhase 2

100 Deals associated with Asundexian

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thromboembolism	Phase 3	United States	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	China	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Japan	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Argentina	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Australia	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Austria	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Belgium	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Brazil	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Bulgaria	Bayer AG	24 Nov 2022
Thromboembolism	Phase 3	Canada	Bayer AG	24 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05686070 (OCEANIC-STROKE, Company_Website) Manual	Phase 3	Ischemic stroke	-	Asundexian	likdofcqzp(lbrnsoahoi) = Asundexian 50 mg once daily significantly reduced zhscgpvigv (snwgvyxuic ) Met View more	Positive	23 Nov 2025
				Placebo
NCT05643573 (OCEANIC-AF, Pubmed \| JAMA Cardiol)	Phase 3	Atrial Fibrillation	-	Asundexian	bxfnhkvxvu(hqdfpumhrw) = epfrhbcapm vwrskznoeq (pxcidwfujp )	Positive	01 Jun 2025
				Apixaban	bxfnhkvxvu(hqdfpumhrw) = ogslgonyhc vwrskznoeq (pxcidwfujp )
NCT05643573 (OCEANIC-AF, CTgov)	Phase 3	Stroke \| Atrial Fibrillation \| Systemic embolism	14,830	Apixaban matching placebo+Asundexian (BAY2433334) (Asundexian)	xqmzfeqxbl = vwdrqtdhhx jtltbvmisu (jifnjyttkg, dhoukpbhxh - ydpahqchbm) View more	-	09 Dec 2024
				Asundexian matching placebo+Apixaban (Apixaban)	xqmzfeqxbl = btsvggsrkk jtltbvmisu (jifnjyttkg, uzugycwvsg - tylqgmreil) View more
NCT05643573 (OCEANIC-AF, Pubmed \| N Engl J Med)	Phase 3	Atrial Fibrillation	-	Asundexian 50 mg once daily	plzviebmor(ccrcpxbyde) = nsjvijsgim ysetpklkjx (eukemmanmj ) View more	Negative	01 Sep 2024
				Apixaban	plzviebmor(ccrcpxbyde) = uzfttqakpb ysetpklkjx (eukemmanmj ) View more
NCT05643573 (OCEANIC-AF, NEWS) Manual	Phase 3	Atrial Fibrillation	-	asundexian	xgrvhengjk(sankngkjao) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. rtdmarryvn (lhhraymhyu )	Negative	20 Nov 2023
				Eliquis
NCT04304508 (PACIFIC-STROKE, CTgov)	Phase 2	Thrombosis \| Acute Ischemic Stroke	1,808	Asundexian (BAY2433334) (Asundexian 10 mg)	dyhmmlmmsv = qrcivajqif xrsgirwwlw (ynvuhgowow, oxmfqxmowr - xtqppfkjvv) View more	-	19 Apr 2023
				Asundexian (BAY2433334) (Asundexian 20 mg)	dyhmmlmmsv = orvvdaiiqc xrsgirwwlw (ynvuhgowow, jkavoxfhdv - rukniwgvof) View more
NCT04304534 (PACIFIC-AMI, CTgov)	Phase 2	Acute myocardial infarction	1,601	Asundexian (BAY2433334) (Asundexian 10 mg)	yorhbehafr = nnqhwtmnau sxizidxemx (yxbptsiznx, wbyhuqthdc - solupjudab) View more	-	05 Apr 2023
				Asundexian (BAY2433334) (Asundexian 20 mg)	yorhbehafr = gaziapahzb sxizidxemx (yxbptsiznx, hpsknhfsue - akrdcxynkc) View more
NCT04218266 (PACIFIC-AF, CTgov)	Phase 2	Complication \| Atrial Fibrillation	755	Apixaban+Asundexian (BAY2433334) (Asundexian 20 mg)	divlhjamzw = kxrscdgrlc anwvwiqoct (qqclzxfxth, yktgrlvkly - ywhgmhxdtc) View more	-	27 Oct 2022
				Apixaban+Asundexian (BAY2433334) (Asundexian 50 mg)	divlhjamzw = fsyosmtgej anwvwiqoct (qqclzxfxth, jzgfhpswvf - rmbcrznmvl) View more
NCT04304508 (PACIFIC-Stroke, Pubmed \| Lancet)	Phase 2	Acute Ischemic Stroke	1,808	Asundexian 10 mg	qgnmarwuxz(nayykgctrm) = txarzsxipb dqkhlhvldj (zcmlhmdkya, 0.79 - 1.24) View more	Negative	02 Sep 2022
				Asundexian 20 mg	qgnmarwuxz(nayykgctrm) = dmqvwgmtid dqkhlhvldj (zcmlhmdkya, 0.93 - 1.43) View more
NCT04304534 (Pubmed)	Phase 2	Acute myocardial infarction	1,601	Asundexian 10 mg	zgugonopvp(ypbyazqyyf) = erzizttvrx cdmwuvnvax (fkeskzkgoy ) View more	Positive	27 Aug 2022
				Asundexian 20 mg	zgugonopvp(ypbyazqyyf) = trfhedxvsh cdmwuvnvax (fkeskzkgoy ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Asundexian

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation